However, when we performed SCoR on ER-negative patients from NKI295, which composed mainly of highly proliferative basal and HER2 subtype breast cancers, we also identified a T-cell signature in patients with better survival (supplementary Fig. S1). This evidence concerns the gene ESR1 and breast cancer.